Genelux Q1 EPS Lowered by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX) – Analysts at Brookline Capital Management cut their Q1 2025 EPS estimates for shares of Genelux in a research report issued on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.23) for the quarter, down from their previous forecast of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.86) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Genelux in a research report on Monday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Genelux has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Stock Down 2.3 %

GNLX opened at $2.54 on Thursday. The stock’s fifty day moving average is $4.04 and its two-hundred day moving average is $3.10. The company has a market capitalization of $88.21 million, a P/E ratio of -2.67 and a beta of -1.41. Genelux has a 52 week low of $1.60 and a 52 week high of $5.89.

Genelux (NASDAQ:GNLX) last issued its earnings results on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).

Institutional Trading of Genelux

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Genelux during the 3rd quarter worth approximately $59,000. Geode Capital Management LLC increased its position in shares of Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after purchasing an additional 89,854 shares in the last quarter. Apollon Wealth Management LLC lifted its holdings in shares of Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Genelux in the 4th quarter worth $51,000. Finally, LifeSteps Financial Inc. grew its stake in Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.